“The Global Biosimilar Monoclonal Antibodies Market will Grow to USD 14,365.06 Million by 2026, at a CAGR of 23.00%
”
FEATURED COMPANIES
- Allergan Plc
- Biocon
- BioXpress Therapeutics SA
- Boehringer Ingelheim GmbH
- Coherus BioSciences, Inc.
- Genor BioPharma Co. Ltd
The Global Biosimilar Monoclonal Antibodies Market size was estimated at USD 4,147.48 Million in 2020 and expected to reach USD 5,087.54 Million in 2021, at a Compound Annual Growth Rate (CAGR) 23.00% to reach USD 14,365.06 Million by 2026.
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
This research report categorizes the Biosimilar Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilar Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilar Monoclonal Antibodies Market, including Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?
6. What is the market share of the leading vendors in the Global Biosimilar Monoclonal Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biosimilar Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Drug Class, the Biosimilar Monoclonal Antibodies Market was studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab.
- Based on Application, the Biosimilar Monoclonal Antibodies Market was studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic is further studied across MAbs in Biochemical Analysis and MAbs in Diagnostic Imaging. The Therapeutic is further studied across MAbs as Direct Therapeutic Agents and MAbs as Targeting Agents in Therapy.
- Based on Region, the Biosimilar Monoclonal Antibodies Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilar Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilar Monoclonal Antibodies Market, including Allergan Plc, Biocon, BioXpress Therapeutics SA, Boehringer Ingelheim GmbH, Coherus BioSciences, Inc., Genor BioPharma Co. Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., and Reliance Life Sciences.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?
6. What is the market share of the leading vendors in the Global Biosimilar Monoclonal Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Allergan Plc
- Biocon
- BioXpress Therapeutics SA
- Boehringer Ingelheim GmbH
- Coherus BioSciences, Inc.
- Genor BioPharma Co. Ltd
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Application Outlook
3.5. Region Outlook
3.6. Competitor Outlook
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Focus on R&D to introduce innovative product pipeline
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facilitie
5.1.3.2. High adoption rate in developing countries
5.1.4. Challenges
5.1.4.1. Stringent regulations with the product approvals and cost structure associated with the manufacturing process
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.2.1. MAbs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal disorders
7.2.1.3. Infectious diseases
7.2.1.4. Pregnancy
7.2.2. MAbs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular diseases
7.2.2.5. Deep vein thrombosis (DVT)
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MAbs as Direct Therapeutic Agents
7.4.2. MAbs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Allergan Plc
12.2. Biocon
12.3. BioXpress Therapeutics SA
12.4. Boehringer Ingelheim GmbH
12.5. Coherus BioSciences, Inc.
12.6. Genor BioPharma Co. Ltd
12.7. Intas Pharmaceuticals Limited
12.8. Novartis AG
12.9. Pfizer, Inc.
12.10. Reliance Life Sciences
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, 2018-2026 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2026
FIGURE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2026 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, 2018-2026 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, 2018-2026 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2026 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2018-2026 (USD MILLION)
FIGURE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2026 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), 2018-2026 (USD MILLION)
FIGURE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2026 (USD MILLION)
FIGURE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2026 (USD MILLION)
FIGURE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, 2018-2026 (USD MILLION)
FIGURE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, 2018-2026 (USD MILLION)
FIGURE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 58. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 75. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 76. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 80. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 85. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 86. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX
FIGURE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 89. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2018-2026 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 28. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 53. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 54. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 55. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 56. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 58. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 59. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 60. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 63. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 64. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 65. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 66. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Application Outlook
3.5. Region Outlook
3.6. Competitor Outlook
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Focus on R&D to introduce innovative product pipeline
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facilitie
5.1.3.2. High adoption rate in developing countries
5.1.4. Challenges
5.1.4.1. Stringent regulations with the product approvals and cost structure associated with the manufacturing process
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.2.1. MAbs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal disorders
7.2.1.3. Infectious diseases
7.2.1.4. Pregnancy
7.2.2. MAbs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular diseases
7.2.2.5. Deep vein thrombosis (DVT)
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MAbs as Direct Therapeutic Agents
7.4.2. MAbs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Allergan Plc
12.2. Biocon
12.3. BioXpress Therapeutics SA
12.4. Boehringer Ingelheim GmbH
12.5. Coherus BioSciences, Inc.
12.6. Genor BioPharma Co. Ltd
12.7. Intas Pharmaceuticals Limited
12.8. Novartis AG
12.9. Pfizer, Inc.
12.10. Reliance Life Sciences
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, 2018-2026 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2026
FIGURE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2026 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, 2018-2026 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, 2018-2026 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2026 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, 2018-2026 (USD MILLION)
FIGURE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2026 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), 2018-2026 (USD MILLION)
FIGURE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2026 (USD MILLION)
FIGURE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2026 (USD MILLION)
FIGURE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, 2018-2026 (USD MILLION)
FIGURE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, 2018-2026 (USD MILLION)
FIGURE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 58. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 75. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 76. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 80. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 85. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 86. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX
FIGURE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 89. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2018-2026 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 28. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 53. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 54. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 55. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 56. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 58. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 59. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 60. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 63. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 64. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 65. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 66. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
- Allergan Plc
- Biocon
- BioXpress Therapeutics SA
- Boehringer Ingelheim GmbH
- Coherus BioSciences, Inc.
- Genor BioPharma Co. Ltd
- Intas Pharmaceuticals Limited
- Novartis AG
- Pfizer, Inc.
- Reliance Life Sciences
Note: Product cover images may vary from those shown
LOADING...
